©The Author(s) 2025.
World J Gastrointest Surg. Nov 27, 2025; 17(11): 111815
Published online Nov 27, 2025. doi: 10.4240/wjgs.v17.i11.111815
Published online Nov 27, 2025. doi: 10.4240/wjgs.v17.i11.111815
Table 9 Advantages and limitations of anti-reflux mucosal intervention in clinical practice (anti-reflux mucosectomy, anti-reflux mucosal ablation, and peroral endoscopic cardial constriction)
| Intervention | Advantages | Limitations | |
| ARMS | ARMS-horseshoe | (1) No artificial device implantation required; (2) Short procedure time, hospital stay, and fast recovery than surgery; (3) Does not preclude future laparoscopic surgery; (4) Low bleeding rate; and (5) Available tissue specimens for pathology | Relative higher stenosis rate than ARMA |
| ARMS-butterfly | (1) The same as ARMS-horseshoe; and (2) Reduced stenosis rate | Relative higher stenosis rate than ARMA | |
| ARMA | ARMA-horseshoe | (1) No artificial device implantation required; (2) Short procedure time, hospital stay, and fast recovery than surgery; (3) Does not preclude future laparoscopic surgery; (4) Lower stenosis rate than ARMS; (5) Low perforation rate; (6) Adjunctive therapy for post-ARMS; and (7) Can be safely re-administered | (1) Tissue specimens for pathological analysis unavailable; and (2) Relative higher bleeding rate than ARMS |
| ARMA-butterfly | (1) The same as ARMA-horseshoe; and (2) Further reduced stenosis rate | (1) Tissue specimens for pathological analysis unavailable; and (2) Higher bleeding rate than ARMS | |
| PECC | PECC-esophagus | (1) Does not preclude future laparoscopic surgery; (2) Short hospital stays, and fast recovery; (3) Easier to conduct than ARMS; (4) Shorter procedure time; (5) Simpler instrumentation required; (6) Lower dysphagia rate than ARMS; and (7) Improves extra-esophageal symptoms | (1) Slight lower therapeutic effective rate; (2) Tissue specimens for pathological analysis unavailable; and (3) Risk of esophageal lesion aggravation |
| PECC-stomach | The same as PECC-esophagus | (1) The same as PECC-esophagus; and (2) May exacerbate dysphagia and bloating | |
| PECC-esophagus & stomach | The same as PECC-esophagus | The same as PECC-stomach | |
- Citation: Zhang ZH, Yang SZ, Lian JJ, Xu AP, Du XJ, Chen T, Xu MD. Application status of endoscopic anti-reflux mucosal interventions in the treatment of gastroesophageal reflux disease. World J Gastrointest Surg 2025; 17(11): 111815
- URL: https://www.wjgnet.com/1948-9366/full/v17/i11/111815.htm
- DOI: https://dx.doi.org/10.4240/wjgs.v17.i11.111815